Clinical Trials Browser

Phase 1/2 × Triple Negative Breast Neoplasms × Magnetic Resonance Spectroscopy × Clear all

NCT01116648 2026-05-28

Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer

Phase 1/2 Active not recruiting

155 enrolled 34 charts

BreastGynecologic

Fallopian Tube Neoplasms, Triple Negative Breast Neoplasms

NCT04345913 2026-05-27

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT05269381 2026-03-12

PNeoVCA

Phase 1/2 Recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Carcinosarcoma, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT07217990 2026-02-17

NoCUT-BC

Phase 1/2 Not yet recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05756166 2025-06-24

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Phase 1/2 Terminated

Triple Negative Breast Neoplasms